Moon Surgical
Moon Surgical (previously MastOR SAS) is a Paris-based, early-stage medical device company, developing a surgical robot for laparoscopy assistance. It is a privately held portfolio company of Sofinnova Partners, financed through the MD Start III Fund. The core technology is derived from joint research between the ISIR robotics lab at Sorbonne University and Professor Brice Gayet, a world-renowned surgeon and pioneer in minimally-invasive surgery.
Sector
Medical Devices
Strategies
MD Start & Capital
Status
Live
Website
www.moonsurgical.com
Anne Osdoit
Partner, Sofinnova Partners - MD Start Strategy
Antoine Papiernik
Chairman & Managing Partner, Sofinnova Partners
Related News
Moon Surgical Launches Maestro™ Platform at Lee Health
Moon Surgical Expands Leadership Team to Accelerate Commercial Growth Across U.S. and Europe
Moon Surgical receives FDA clearance for ScoPilot™ on Maestro, industry's first AI-enhanced intraoperative capability, powered by NVIDIA Holoscan
Global debut in an ASC setting at Surgeon's Point Surgery Center for Moon Surgical's Maestro System
Moon Surgical appoints Chris Toth as Independent Board Member ahead of commercial acceleration
Enhanced data security and quality via ISO 27001:2022 and SOC 2 certifications enables Moon Surgical to deliver actionable insights to healthcare providers
Moon Surgical receives second FDA clearance, covering its commercial Maestro™ surgical robotics system
Moon Surgical expands to gynecological surgery
Moon Surgical's Maestro System powered by NVIDIA Holoscan paves the way to next-generation laparoscopy, with over 200 patients treated
Arnault Tzanck Institute in Nice, France, completes inaugural robotics surgeries with Moon Surgical's Maestro commercial system
Moon Surgical announces CE Mark for its commercial Maestro System
Moon Surgical's first-in-human trials feature in major surgical publication
Maestro, Moon Surgical's rising star
Moon Surgical appoints Fred Moll, MD, as Board Chair and raises additional $55.4 million in new funding with leading investors Sofinnova Partners and NVIDIA
Moon Surgical appoints Anne Renevot as Chief Financial Officer
Maestro Surgical Robotics System by Moon Surgical, Now CE Marked
Moon Surgical completes first-in-human clinical study with its Maestro™ Surgical Robotics System
Moon Surgical receives first FDA 510(k) clearance for its Maestro(TM) Surgical Robotics System
Moon Surgical announces appointment of Mark Toland as Independent Board Member
Moon Surgical raises $31.3 million to accelerate development of Maestro Robotic System
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.